Stuart Therapeutics has secured the exclusive rights to collagen mimetic peptides (CMPs) of unique design, which mimic human collagen, and have application in human and veterinary therapeutics and diagnostics. They have an amino acid sequence identical to a single strand of human type I collagen, and are non-immunogenic. The Stuart Therapeutics team has enhanced the value of these peptides by filing for US and international patents protecting a variety of medical applications of this technology, creating a novel therapeutic platform — PolyCol.

When used in various clinical applications, PolyCol targets, anchors to and repairs damaged collagen in the body, which is present in many diseases and trauma conditions. PolyCol can also chemically link to and deliver both small molecule therapeutics and biologics, enhancing their therapeutic outcomes, reducing dosage and frequency of administration. Stuart Therapeutics’ patent filings relating to PolyCol cover novel therapeutic compounds and their use in a variety of conditions such as certain cancers, rheumatoid arthritis, various acute and chronic skin conditions, ophthalmic conditions, digestive diseases and many others.

PolyCol’s linking chemistry options offer a number of different bioavailability approaches for therapeutics, including extended release and delayed release. PolyCol’s composition, variations, and applications are more fully described in the Stuart Therapeutics white paper, “PolyCol, A New Topical Therapeutic,” which describes the science behind collagen, collagen mimetic peptides, and PolyCol, along with its proposed applications.

Stuart Therapeutics has completed a series of animal proof of concept tests that demonstrate the unique ability of PolyCol to accelerate the healing of damaged collagen in ocular surface conditions, suggesting that PolyCol has therapeutic benefit for many indications which include damaged collagen, including dry eye and corneal ulcers of any etiology. The therapeutic ST-100 is in pre-clinical development to address these ocular surface disease indications.